The genetic fingerprint

The biology of a melanoma and the defense response within the skin differ from individual to individual. Therefore, your treatment should also be tailored to your individual needs. Once MelaGenix has provided you with knowledge of your personal relapse risk, your physician can decide whether treatment is necessary.

Standard procedure:
Histological tissue examination

New: More precise prognosis by

Even after the complete surgical removal of a melanoma, about 15% of all patients are not permanently cured. Individual tumor cells can spread, causing a relapse. This affects also patients who have been diagnosed with an early stage of cutaneous malignant melanoma.

Your genes have an impact on your disease. Therefore standard tissue examination cannot safely predict the course of your disease and your relapse risk. The MelaGenix gene expression test captures the genetic fingerprint (signature) of your melanoma and your surrounding skin tissue to precisely assess your relapse risk.

MelaGenix helps you and your physician to make the best possible decisions regarding further melanoma treatment and follow-up.

The tumor reveals its secret

The MelaGenix gene expression test determines the biological activity of 8 disease-relevant genes in the melanoma and surrounding skin tissue. Using those activity data, MelaGenix calculates your relapse risk within the next few years.

MelaGenix gene signature assayEight genes for precise risk assessment

The test does not require further surgical intervention. The gene activity analysis is carried out using the available primary tumor tissue that was routinely preserved after your surgery.

In consultation with your physician you should perform the MelaGenix gene expression test as soon as possible after diagnosis to obtain more security in further treatment and follow-up care decisions.

Even if some time has passed since the diagnosis, MelaGenix can be performed. The test always stays reliable and will answer the question regarding your relapse risk.

Ask your doctor about MelaGenix today.

Extra security

MelaGenix completes your diagnosis and helps your physician to make more accurate decisions on your therapy. The precise knowledge about your relapse risk will increase the security of managing your melanoma. Together, you and your doctor can choose the best option that not only reduces hazards but also significantly increases your chances of recovery and cure.

Reclassification of your relapse risk by MelaGenix (for the first 5 years after diagnosis):

Melanoma at an early stage (stage I):

The relapse risk in stage I is usually regarded as low (about 10%) and further treatment is not prescribed. Yet a completely different picture may present itself after performance of the MelaGenix test: the test can identify patients with an increased relapse risk of 50%. As a high-risk patient, you require more intensive follow-up care and potentially also drug therapy to prevent a relapse.

Melanoma at an intermediate stage (stage II):

Frequently, Stage II patients receive the offer for drug therapies to lower their relapse risk. If MelaGenix confirms a high relapse risk, you can decide to opt for this treatment. Should your relapse risk be low (about 10%) even without treatment, your physician will discuss with you the option of foregoing an adjuvant therapy, to avoid unnecessary side effects.

Melanoma at an advanced stage (stage III):

At stage III, the result of your MelaGenix test changes the course of your further treatment even if the initial diagnosis and subsequent treatment with drugs have been concluded. In case of a high relapse risk (75%), your physician can advise you whether additional targeted treatment forms are necessary. Thereby an impending relapse can be counteracted as early and comprehensively as possible to increase your chances for a cure.

Your physician will explain the significance of the MelaGenix test results to you with respect to further treatment and follow-up.

Active for more security
(– it´s in your hands)

The MelaGenix gene expression test helps you and your physician to better assess your personal relapse risk. This means more security in treating your melanoma.

MelaGenix is particularly suited for melanoma patients who have been diagnosed in the early or intermediate stage (I and II). The test can also be of great value in planning your treatment of advanced stage (III) melanoma.

After your physician has ordered the MelaGenix gene expression test, NeraCare will request your primary melanoma tissue sample from the relevant pathology laboratory. The MelaGenix test is then performed under certified and accredited conditions at a molecular biology laboratory. The test assesses your relapse risk. The test result will be forwarded to your consulting physician within 2 to 3 weeks.

Immediately after confirmation of your diagnosis, you will discuss various forms of treatment with your physician. Here it is important for you to know your exact personal relapse risk in the next few years in order to weigh the risks and benefits of potential treatments together with your physician.

To obtain more security in the planning of your treatment and follow-up care you should perform the MelaGenix gene expression test as early as possible in consultation with your physician. Please contact your consulting physician should you decide to have the MelaGenix gene expression test performed. MelaGenix is prescribed and requested by your physician.

The reimbursement of costs

The MelaGenix gene expression test has been available since 2015 and some private insurances in Germany already reimburse the costs of the test on a case-to-case basis. Patients would have to initially shoulder the full cost of the gene test. A 50% down payment is required through money transfer or credit card upon placement of the order. The remaining 50% is due upon delivery of the MelaGenix Risk Score to your consulting physician. Depending on your country, some private health insurances and medical aid authorities may be willing to cover the costs of the gene test. Please contact your insurance provider for information on reimbursement options.